CRONNasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends December 31

Cronos Group Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$3.25+0.04 (+1.25%)

Close on Oct 19, 2026

Market cap: $1.22B
P/E (TTM): 16.3
Dividend yield: –

Cronos Group Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31
Revenue	147	118	87	87	65	47	24	12	3.15	–
Gross Profit	63	25	12	15	-18	-26	-18	6.21	1.57	–
Research & Development	4.45	4.23	5.84	13	22	20	12	1.81	0	–
Selling, General & Admin	64	68	72	86	112	115	105	16	5.35	–
Selling & Marketing	22	22	23	18	21	34	23	2.54	0.44	–
General & Administrative	42	47	49	68	91	81	81	13	4.90	–
Advertising Expenses	2.27	0.89	1.38	0.89	2.23	6.09	1.29	–	–	–
Operating Expenses	80	102	97	127	274	194	136	27	7.70	–
Operating Income	-17	-77	-85	-111	-292	-219	-153	-20	-6.12	–
Interest Expense	–	–	–	0.01	0.03	0.19	1.24	0.14	0.10	–
Interest & Investment Income	–	–	–	23	9.10	19	29	0.22	0.00	–
Income from Equity Investments	0	2.37	1.58	3.11	-6.31	-4.51	-2.01	-0.72	0.13	–
Other Non-Operating Income	0.28	113	11	-9.58	163	146	1,319	-0.48	3.78	–
Merger & Restructuring Charges	2.04	0.63	1.52	3.55	0	0	5.33	0	0	–
Asset Impairment Charges	0.70	0	0	3.49	0.04	40	0	0	–	–
Gain (Loss) on Investments	-0.45	-3.84	-11	18	1.97	-4.51	–	–	–	–
Pretax Income	-17	37	-74	-121	-129	-73	1,166	-21	-2.35	–
Income Tax Expense	-14	-3.44	-3.23	34	-0.43	1.35	0	0	-0.86	–
Income from Continuing Operations	-2.93	40	-70	-155	-128	-75	1,166	-21	–	–
Income from Discontinued Operations	0	0	-4.11	-14	-269	-0.65	-0.36	-0.89	–	–
Net Income incl. Noncontrolling Interests	-2.93	40	-75	-169	-397	-75	1,166	-22	-1.48	–
Minority Interest in Earnings	6.52	-1.06	-0.59	0	-1.10	-2.13	-0.93	-0.18	0	–
Net Income	-9.45	41	-74	-169	-396	-73	1,167	-22	-1.48	–
Net Income to Common	–	–	–	–	–	-72	1,167	-21	-1.48	–
EPS (Basic)(per share)	-0.02	0.11	-0.19	-0.45	-1.07	-0.21	3.76	-0.12	-0.01	–
EPS (Diluted)(per share)	-0.02	0.11	-0.19	-0.45	-1.07	-0.21	3.33	-0.12	-0.01	–
Shares Outstanding (Basic, Weighted)(shares)	383	382	381	377	370	352	310	172	135	78
Shares Outstanding (Diluted, Weighted)(shares)	383	386	381	377	370	352	343	172	177	78
EBITDA	-3.16	-67	-77	-98	-277	-212	-149	-19	-5.35	–
Provision for Credit Losses	4.86	-11	-1.53	-0.66	12	2.44	0.14	0	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 45.9%
Operating margin: -1.4%
Net margin: 39.1%
Return on equity, FY2025: -0.9%

Financial strength

Current ratio: 16.18
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 828.6%

Valuation

P/E ratio: 16.3
Price to sales: 6.81
Price to book: 1.14
Dividend yield: –